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Free radicalsHeme oxygenase-1 (HO-1) is an antioxidative and cytoprotective enzyme, which may protect neoplastic cells
against anticancer therapies, thereby promoting the progression of growing tumors. Our aim was to
investigate the role of HO-1 in cancer induction. Experiments were performed in HO-1+/+, HO-1+/−, and HO-
1−/−mice subjected to chemical induction of squamous cell carcinomawith 7,12-dimethylbenz[a]anthracene
and phorbol 12-myristate 13-acetate. Measurements of cytoprotective genes in the livers evidenced systemic
oxidative stress in the mice of all the HO-1 genotypes. Carcinogen-induced lesions appeared earlier in HO-
1−/− and HO-1+/− than in wild-type animals. They also contained much higher concentrations of vascular
endothelial growth factor and keratinocyte chemoattractant, but lower levels of tumor necrosis factor-α and
interleukin-12. Furthermore, tumors grew much larger in HO-1 knockouts than in the other groups, which
was accompanied by an increased rate of animal mortality. However, pathomorphological analysis indicated
that HO-1−/− lesions were mainly large but benign papillomas. In contrast, in mice expressing HO-1, most
lesions displayed dysplastic features and developed to invasive carcinoma. Thus, HO-1 may protect healthy
tissues against carcinogen-induced injury, but in already growing tumors it seems to favor their progression
toward more malignant forms.icz).
 license.© 2011 Elsevier Inc.Open access under CC BY license.Hemeoxygenases (HOs) are the rate-limiting enzymes in catabolism
of heme that convert it to the biologically active products carbon
monoxide (CO), biliverdin, and ferrous iron [1]. Two distinct variants of
HOs have been described in humans and rodents: HO-2, present at high
levels in the brain, testes, or endothelial cells [2], and HO-1, which is
strongly induced in many cell types by heme, heavy metals, inﬂamma-
tory cytokines, UV irradiation, and reactive oxygen species [3].
Expression of HO-1 is usually higher in cancer cells than in surrounding
healthy tissues, as shown for lymphosarcoma, prostate cancers, brain
tumors, adenocarcinoma, hepatoma, squamous carcinoma, glioblasto-
ma, melanoma, Kaposi sarcoma, or pancreatic carcinoma [4–12]. HO-1
can be directly induced by some oncogenes, such as viral G-protein-
coupled receptor encoded by Kaposi sarcoma-associated herpes virus or
BCR/ABL fusion kinase [10]. The potential meaning of such induction for
oncogenesis has not been investigated yet.Expression of HO-1 in tumors can be further elevated in response
to chemo-, radio-, or photodynamic therapies, possibly as a result of
oxidative stress [10,14,15]. There are several lines of evidence
showing that HO-1 exerts potent and comprehensive protumoral
effects in growing tumors. Its upregulation improves the survival of
various tumor cell lines exposed to stressful agents both in vitro
[8,16–20] and in vivo [21,22]. It may also inﬂuence the cell cycle
progression in neoplastic tissues. Downregulation of HO-1 has been
shown to inhibit the growth of a pancreatic tumor cell line [13],
whereas overexpression of HO-1 in human and murine melanoma
cells increased signiﬁcantly their proliferation [20]. These effects seem
to be strongly cell-type-dependent, as HO-1 activity exhibited anti-
proliferative actions in human and rat breast cancer cell lines [23]. HO-1
can also promote tumor angiogenesis and metastasis as demonstrated
in humans [11,24] and in animal models [20,22,25]. Its overexpression
in melanoma cells [20] and pancreatic cancer cells [26] increased
colonization of lungs, whereas inhibition of HO activity completely
inhibited formation of pulmonary metastases [26].
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concerning its possible inﬂuence on tumor induction are very limited.
Some indications come from clinical studies on polymorphisms of the
HO-1 promoter, in which the presence of less active allelic variants
seems to correlate with a higher incidence of lung cancer or squamous
cell carcinoma (SCC) in smokers or areca chewers, respectively [27,28],
suggestingaprotective role forHO-1 in cancer induction. This supposition
has not been veriﬁed under controlled, experimental conditions.
Therefore, our aim was to examine the effect of HO-1 on the induction




7,12-Dimethylbenz[a]anthracene (DMBA), phorbol 12-myristate
13-acetate (PMA), Triton X-100, phenylmethylsulfonyl ﬂuoride,
leupeptin, aprotinin, heparin, bicinchoninic acid protein assay kit,
eosin, hematoxylin, and SYBR Green Jump Start Taq Ready Mix for
High Throughput QPCRwere purchased from Sigma (Poznan, Poland).
Acetone, chloroform, ethanol, and xylene were procured from Polskie
Odczynniki Chemiczne (Gliwice, Poland). Qiazol was obtained from
Qiagen (Hilden, Germany) and BrdU Cell Proliferation ELISA from
Roche Diagnostics (Warsaw, Poland). A total RNA extraction kit and
reverse transcription system were obtained from Promega (Gdansk,
Poland). ELISA kits for mouse vascular endothelial growth factor
(VEGF), VEGF receptor-1 (VEGFR-1), tumor necrosis factor (TNF),
sTNF-RI, keratinocyte attractant (KC), interleukin-1β (IL-1β), IL-6, IL-
12, SDF-1α (stromal cell-derived factor-1α), and granulocyte colony
stimulating factor (G-CSF) were procured from R&D Systems
(Warsaw, Poland). Antibody for proliferating cell nuclear antigen
(PCNA) detection was purchased from DAKO (Warsaw Poland) and
FACS lysing solution from Becton–Dickinson (Gliwice, Poland).
Animals
Experiments were performed on HO-1−/− (N=11), HO-1+/−
(N=13), and HO-1+/+ (N=12) females of C57BL/6×FVB mice,
generated from the HO-1+/− breeding pairs kindly gifted by Dr.
Anupam Agarwal (Birmingham, AL, USA). The ﬁrst treatment was
conducted onmice at the age of 9 weeks. All procedures were approved
by the Institutional Animal Care and Use Committee at Jagiellonian
University.
Chemical carcinogenesis
A single dose of DMBA (100 nmol in 100 μl of acetone) was applied
on shaved dorsal skin. Applications of PMA (5 nmol in 100 μl of
acetone) started 2 weeks later and were repeated twice a week for
28 weeks. All manipulations were performed under anesthesia
induced by inhaled isoﬂurane. Once a week the animals were
weighed, and tumor sizes and locations were documented. Tumor
volumes were determined by means of caliper and calculated using
the following formula: V=D×d2×0.52 (V is the tumor volume, D is
the biggest dimension; d is the smallest dimension).
Hematoxylin–eosin (H&E) analysis
Skin tumors, collected at the end of the experiment (28thweek) or on
the day of death of particular animals (12–27 weeks), were ﬁxed in
neutral buffered formalin, embedded in parafﬁn, sectioned (6 μm), and
stainedwith H&E. All slideswere investigated in a blinded fashion by two
pathologists (A.R. and A.P.) and assessed for tumor architecture,
keratinocyte differentiation, cytologic atypia, and inﬂammation. Tumors
were classiﬁed as follows: (i) typical papillomas—tumors showingpapillomatous architecture and consisting of well-differentiated kerati-
nocytes without cytologic atypia, withmitotic ﬁgures limited to the basal
and lower epidermis; (ii) atypical papillomas—tumors with similar
architecture, but comprising keratinocytes with cytologic atypia and
augmentedmitotic ﬁgures not limited to the lower epidermis; (iii) SCC in
situ—tumors demonstrating keratinocyte cytologic atypia and mitotic
ﬁgures involving the entire epidermis; and (iv) invasive SCC—tumors in
which the clear penetration or disruption of the basement membrane by
malignant keratinocytes was detected. Additionally, the semiquantitative
assessment of inﬂammatory inﬁltrate, erythrocyte extravasation, and
necrotic areas (0—no, 1—weak, 2—moderate, 3—strong reaction) was
performed in a blinded fashion by two pathologists (A.R. and A.P.).
PCNA staining
Staining was performed on parafﬁn sections after heat-induced
epitope retrieval (0.01 M citric acid, pH6.0, 95 °C, 3×4 min). Specimens
were blocked (10% goat serum in TBS, room temperature, 60 min) and
incubated with primary antibody (diluted 1:200 in TBS) overnight at
4 °C. After beingwashed in TBS, the specimenswere incubated for 1 h at
room temperature with secondary antibody (diluted 1:200 in TBS)
conjugated with Alexa Fluor-546. Then the specimens were embedded
in 4′,6-diamidino-2-phenylindole-containing medium. Negative con-
trol was prepared with the primary antibody omitted.
Preparation of tissue lysates
Tumors and fragments of the liver isolated from each animal were
homogenized using an automatic tissue lyser (Qiagen) in ice-cold
PBS containing 1% Triton X-100 and protease inhibitors (1 μg/ml
phenylmethylsulfonyl ﬂuoride, 1 μg/ml leupeptin, and 1 μg/ml
aprotinin). Then the samples were incubated for 30 min on ice and
centrifuged (21,000g, 10 min, 4 °C). Clear supernatants were collect-
ed and total protein concentrations were determined by the
bicinchoninic acid protein assay kit, according to the vendor's
protocol.
ELISA
Concentrations of proangiogenic and proinﬂammatory cytokines
were measured in blood sera or tumor lysates using colorimetric
sandwich ELISA according to the vendor's instructions.
RNA isolation and real-time PCR
Fragments of liver isolated from each animal were homogenized in
1 ml of Qiazol and mixed with 300 μl of chloroform. The obtained lysates
were vortexed, incubated on ice for 30 min, and centrifuged (30 min,
10,000g, 4 °C). Then, an upper aqueous phasewas collected and subjected
to ethanol precipitation. The RNA pellet was dissolved in nuclease-free
water. Reverse transcriptionwas performed on 1 μg of total RNA for 1 h at
42 °C using oligo(dT) primers and AMV reverse transcriptase. Real-time
PCR was carried out using a Rotor Gene RG-3000 (Corbett Research) in a
mixture containing SYBR Green PCR Master Mix, speciﬁc primers, and
30 ngof cDNA ina total volumeof 15 μl. PCRswereperformed induplicate
using a 5-min incubation at 94 °C followed by 40 three-step cycles of 30 s
at 94 °C, 60 s at 60 °C, and 45 s at 72 °C. Relative gene expression
was calculated with the ΔCT method, with the elongation factor-2
(EF2) geneused asan internal control. The followingprimerswereused:
5′-GACATCACCAAGGGTGTGCA (EF2 F), 5′-TCAGCACACTGGCATAGAGG
(EF2 R); 5′-GTGGAGACGCTTTACGTAGTGC (HO-1 F), 5′-CTTTCA-
GAAGGGTCAGGTGTCC (HO-1 R); 5′-TGACCGAGCAGAAAATACCC
(HO-2, F), 5′-GAAGTAAAGTGCAGTGGTGGC (HO-2, R); 5′-CCCCAA-
GATCCCGAACCTCT (biliverdin reductase, BVR F), 5′-TCAAGGCTCC-
CAAGTTCTCGTC (BVR R); 5′-GCTAGAGAAGATGGTCGCCAAGCAG
(thioredoxin-2, Thrx-2 F), 5′-TCCTCGTCCTTGATCCCCACAAACTTG
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SOD-1 F), 5′-ATGGACGTGGAACCCATGCT (SOD-1 R); 5′-AATCT-
CAACGCCACCGAGGA (SOD-2 F), 5′-TCTCCTTTGGGTTCTCCACCA
(SOD-2 R); 5′-CTTCGAGCCTGAGCCCTTTG (ferritin F), 5′-CAGGTT-
GATCTGGCGGTTGA (ferritin R); 5′-TGACATGGTCTGGGACTTCTGG
(catalase F), 5′-TTGATGCCCTGGTCGGTCTT (catalase R); 5′-
CCCCTTTCCCTCTGCTGAAG (glutathione S-transferase-1, GSTA-1 F),
5 ′ - TGCAGCTTCACTGAATCTTGAAAGC (GSTA-1 R) ; 5 ′ -
GGCACTTGCGTGAATGTTGG (glutathione reductase, GR F), 5′-
GGCATCCCTTTTCTGCTTGATG (GR R); 5′-GTCCAATCCTGGTGATGT
(p21 F), 5′-GTTTTCGGCCCTGAGATG (p21 R); 5′-ACTACCTG-
GACCGCTTCCTGT (cyclin D1 F), 5′-GATGAAATCGTGGGGAGTCATG
(cyclin D1 R); 5′-ATTTCAAGTGCGTGCAGAAGGA (cyclin D2, F), 5′-
GTCAGCGGGATGGTCTCTTT (cyclin D2, R); 5′-CTCCTACTTC-
CAGTGCGTCAA (cyclin D3, F), 5′-CAATAGTCAGGGGCGTGGTTTC
(cyclin D3 R).Gene proﬁle screening
An expression proﬁle of genes regulating the cell cycle was
analyzed using the GEArray Q series assay (SuperArray Biosciences,
Bethesda, MD, USA) according to the vendor's protocol.Isolation of primary ﬁbroblasts
Analysis of gene expression in tumors is hampered by hetero-
geneity of the tissue. Therefore, to investigate the inﬂuence of HO-1
on the cellular response to DMBA, we isolated primary ﬁbro-
blasts from the skin of mice and incubated them in the presence of
DMBA (5 μM). Additionally, to investigate the role of HO-1 in cell
transformation, we transduced the ﬁbroblasts with c-myc, using
retroviral vectors.
Fragments of skin taken frommurinenewbornswere digested for 6–
8 h at 37 °C with a mixture containing collagenase type II (1.5 mg/ml)
dissolved in Dulbecco's modiﬁed Eagle's medium (DMEM) LG supple-
mented with penicillin (100 U/ml), streptomycin (100 μg/ml), Gluta-
max (2 mM), and 20% fetal bovine serum (FBS; for later passages and
regular culture 10% FBS was applied). The obtained cell suspension was
gently mixed and centrifuged (1100g, 10 min, at room temperature).
Supernatant was discarded, whereas cells were resuspended in culture
medium and plated. On the third day ﬁbroblasts were washedwith PBS
and cultured under standard conditions. Cells at passages 3 and 4 were
used for experiments.Production of retroviral vectors and transduction of ﬁbroblasts
Retroviral vectors were produced using the Phoenix-Eco HEK293
packaging cell line. Cells were cotransfected with plasmids pBabe
encoding the murine c-myc gene and pM13 harboring the gag and pol
genes, using SuperFect, according to the vendor's protocol. Control
vectors were produced using pM13 and pLZRS plasmids bearing the
enhanced yellow ﬂuorescent protein (EYFP) gene. Media containing
retroviruses were collected 48 h after cotransfection and frozen at
−80 °C or immediately mixed with an equal volume of DMEM
supplemented with Polybrene (4 μg/ml) and used for transduction of
ﬁbroblasts.
Primary ﬁbroblasts were grown to ~60% conﬂuency. Just before
transduction thecellswerewashedwithPBSandoverlaidwith retroviral
solution for 3 days. Afterward viruses were removed, and the ﬁbroblasts
were cultured for the next 3 days and then subjected to RNA or protein
isolation. In each experiment the efﬁcacy of transduction was ~30% for
all genotypes as assessed in control cells treated with retroviral vectors
harboring the EYFP reporter gene.Kinase activity assay
Measurement of phosphorylation of Akt and S6 ribosomal protein
was done using the PathScanMultiplexWestern Cocktail I Detection Kit
(Cell Signaling Technology,Warsaw, Poland) according to themanufac-
turer's instructions. In short: untreated or c-myc-overexpressing cells
were seeded in six-well plates and grown to about 50% conﬂuency. Then
some samples were stimulatedwith DMBA at the ﬁnal concentration of
5 μmol/L. Proteins were isolated after a 72-h incubation period.
Protein samples (15 μg) were diluted in dH2O to a ﬁnal volume of
33 μl, mixedwith 7 μl of Protein Loading Buffer, and denatured for 5 min
at 95 °C. Then the proteins were separated by SDS–PAGE using 4%
stacking and 12% running gels, at 100 and 200 V, respectively. Transfer
to the nitrocellulosemembranewas run at 4 °C for 1.5–2 h at 100 V. The
membranewas stainedwith Ponceau S for 2 min to visualize theprotein
bands. Then, the stain was removed by triple washing with dH2O. The
membrane was blocked in 5% nonfat dry milk in 1× TBS with 0.05%
Tween 20 for 1 h at room temperature,washed six times for 5 min in 1×
TBS with 0.05% Tween 20, and incubated overnight with primary rabbit
antibody cocktail diluted 1:200 in a dilution buffer (5% albumin in 1×
TBSwith 0.05% Tween 20) at 4 °C. Next, themembranewaswashed and
incubated for 1 h with horseradish peroxidase (HRP)-conjugated
secondary antibody (1:1000) in a dilution buffer (5% nonfat dry milk
in 1× TBS with 0.05% Tween 20) at room temperature. Then, the
membranewaswashed and incubatedwith an HRP substrate for 5 min,
followed by membrane development.
Cell proliferation assay
Proliferation of ﬁbroblasts was measured using a bromodeoxyur-
idine (BrdU) ELISA according to the vendor's protocol. Brieﬂy: primary
ﬁbroblasts (5000 cells/well) were seeded in 96-well plates, starved for
24 h in the absence of FBS, and then stimulatedwithmediumcontaining
10% FBS for the next 24 h. Unstimulated cells served as a controls. BrdU
(ﬁnal concentration of 10 μmol/L) was added to the cell cultures for the
last 2 h. The mediumwas removed, and the cells were dried, ﬁxed with
FixDenat (100 μl per well, 30 min), and incubated with anti-BrdU
antibody (1:100, 1.5 h, room temperature). The cellswerewashed three
times and incubated with substrate solution (15 min, incubation at
room temperature in darkness). The reaction was stopped with 1 M
H2SO4 and absorbance was measured at the wavelength 450 nm.
Cell motility assay
Migration of ﬁbroblasts was analyzed using a modiﬁed Boyden
chamber (8-μm pore diameter). Cells (150,000 per well) were seeded
on the transwell insert in 300 μl of medium devoid of FBS but
supplemented with 5% bovine serum albumin. To the lower part,
500 μl of the same medium with or without FBS (10%) was added.
Migration was assessed 24 h later: cells on the lower surface of inserts
were ﬁxed and stained with crystal violet (CV) solution. Quantiﬁca-
tion of migration was performed by measurement of absorbance after
methanol extraction of CV at the wavelength 570 nm.
Semiliquid agarose clonogenic test
Agarose (0.8 and0.4%)wasdissolved in sterilewater and autoclaved.
Warmed 0.8% agarose was mixed with 2× DMEM (1:1 v/v) and 2 ml of
themixture was placed in eachwell of a six-well plate. Cell suspensions
(2×104 cells/ml) were prepared in 2×DMEM,mixedwith 0.4% agarose
(1:1 v/v), and gently poured on a 0.8% agarose layer (1 ml/well). Plates
were incubated under standard conditions for 7 days and then colonies
were counted under the microscope in 50 random ﬁelds of view. In all
experiments, B16(F10) murine melanoma cells were used as a positive
control, and untreated primary ﬁbroblasts served as a negative control.
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Tumor cells were seeded on plates (100,000 per well) and cultured
for 48 h. Then, the cells were washed twice with PBS, scraped, and
centrifuged (10,000g, 10 min, 4 °C). Pellets of cells were snap-frozen
in liquid nitrogen and production of CO was quantiﬁed using gas
chromatography as described elsewhere [29].
Statistical analysis
Results are presented as means±SEM of at least three indepen-
dent experiments. Statistical signiﬁcance was determined using
Student's t test or Fisher's exact test. Kaplan–Meier analysis was
used to compare the time course of observed effects.
Results
Effect of HO-1 expression on sensitivity to carcinogens
Treatment of mice with DMBA and PMA led to the development of
skin lesions resembling papilloma, which gradually progressed to
squamous cell carcinoma. This was conﬁrmed by macroscopic
observations and by morphological analysis of parafﬁn-embedded
tissues stained with H&E, by which specimens were classiﬁed asFig. 1. Histological analysis of tumors. Lesions were classiﬁed as follows: (A) normal epithelium,
Hematoxylin and eosin staining on parafﬁn-embedded sections. Original magniﬁcation: 170× (A)normal epithelium (Fig. 1A), hyperplasia (Fig. 1B), papilloma (Fig. 1C),
papilloma atypicum (Fig. 1D), or carcinoma (Fig. 1E). Metastatic
inﬁltration to the local lymph nodes was observed in mice with the
most advanced tumors (Fig. 1F).
Experiments were performed in mice of different HO-1 genotypes.
Importantly, the ﬁrst lesions appeared 2 weeks later in the wild-type
group than in their HO-1−/− and HO-1+/− counterparts (Fig. 2A).
Such delay in induction of papilloma development was observed in
animals with a normal level of HO-1 during the whole time course of
the experiment (Pb0.05 for comparison of HO-1+/+ and HO-1+/−
and P=0.061 for comparison of HO-1+/+ and HO-1−/−, Kaplan–
Meier test). Thus, induction of lesions in 50% of the treated animals
required recurrent PMA applications for 9 weeks in the HO-1−/−, 8 in
the HO-1+/−, and 12 in the HO-1+/+ mice, whereas tumors appeared
in all individuals respectively after 17, 25, and 26 weeks. We also
found that lack of HO-1 expression was associated with reduced
weight gain (Fig. 2B) and increased mortality of animals (Fig. 2C).
Thus, survival rate at the end of the experiment was 82% in HO-1+/+,
69.2% in HO-1+/−, and only 41.7% in HO-1−/− individuals (Pb0.05 for
comparison of HO-1+/+ and HO-1−/−, Kaplan–Meier test).
The volume of nodules in the wild-type animals increased much
more slowly than in the other genotypes, and even at the last week of
experiments the tumors remained small (Figs. 3A and B). Interestingly,
there were apparent differences in lesion progression between HO-(B) hyperplasia, (C) papilloma, (D) atypicum papilloma, (E) carcinoma, and (F) metastases.
, 340× (B, D, E), or 80× (F).
Fig. 2. Tumor development and survival of mice of different HO-1 genotypes treatedwith
DMBA/PMA. (A) Time course of latency to the ﬁrst tumor (Pb0.05 HO-1+/− vs HO-1+/+,
P=0.061 HO-1−/− vs HO-1+/+). Each point represents themean±SEM. (B) Time course
of bodyweight increase (*Pb0.05HO-1−/− vsHO-1+/+). (C) Survival ofmice (Pb0.05HO-
1−/− vs HO-1+/+).
Fig. 3. Sizes and numbers of DMBA/PMA-induced tumors in mice of various HO-1
genotypes. (A) Representative photos of tumors at the end of the experiment. (B) Mean
volume of tumors. (C) Mean number of tumors (*Pb0.05 HO-1−/− vs HO-1+/+,
$Pb0.05 HO-1+/− vs HO-1+/+). Each point represents the mean±SE.
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animals resulted in the generation of more numerous but still relatively
small nodules (Figs. 3A, B, and C). A complete lack of HO-1 in HO-1−/−
individuals led to the formation of few (sometimes single) tumors, but
their volume was large, much bigger than in the other experimental
groups (Figs. 3A, B, and C). At the 28th week of treatment the average
tumor volume was 8.62±1.91 mm3 in HO-1+/+, 25.52±9.38 mm3 in
HO-1+/− (Pb0.01, Student's t test), and 63.12±42.55 mm3 inHO-1−/−
mice (Pb0.05, Student's t test). Taken together, these observations
indicate that expression of HO-1 may protect animals from the DMBA/
PMA-induced skin injury and development of lesions.
It should be kept in mind, however, that HO-1 is not the only
source of HO activity. Measurement of CO production in cells isolated
from the tumors and cultured in vitro showed only an ~45% decrease
in CO generation by HO-1−/− cells (10.2 and 5.7 nmol/h/mg protein in
HO-1+/+ and HO-1−/− cells, respectively). This indicates relatively
high activity of HO-2. Accordingly, qRT-PCR analysis conﬁrmed the
expression of HO-2 in tumors, at similar levels in HO-1+/+ and HO-
1−/− samples (respectively 0.259±0.055 and 0.207±0.044, HO-
2/EF2 relative expression).
Surprisingly, pathomorphological analysis of H&E-stained speci-
mens evidenced that the nodules on HO-1−/− mice, although large,
displayed features of benign papilloma. Namely, at the end of theexperiment, dysplastic foci in tumors were observed in only 1 of 6 HO-
1−/− individuals (16.7%). In contrast, even low levels of HO-1 in lesions
(in HO-1+/− animals) were associated with a higher grade of tumor
malignancy, suggesting that expression of HO-1 may facilitate malig-
nant transformation of growing tumors. Dysplastic foci or features
typical of inﬁltrating squamous cell carcinomawere found in 8 of 9 HO-
1+/− individuals (88.9%) and in all 10 HO-1+/+ mice. Differences
between genotypes were statistically signiﬁcant (Pb0.001, Fisher's
exact test).
Effect of HO-1 on expression of inﬂammatory and angiogenic factors
To monitor the carcinogen-induced systemic inﬂammatory reac-
tion of mice we periodically checked the frequency of major leukocyte
populations in the peripheral blood, using ﬂow cytometric SSC/FSC
dot-plot analysis (Figs. 4A–C). In healthy HO-1−/− animals the
frequency of monocytes was higher than in the two other groups
(Fig. 4A). Similarly, 2 weeks after topical application of DMBA
monocytes constituted 4.7±0.6, 4.7±0.6, and 17.1±5.2% of periph-
eral blood leukocytes in HO-1+/+, HO-1+/−, and HO-1−/−mice. Two
weeks after the ﬁrst PMA treatment the level was raised to 27.2±5.9%
in HO-1 knockouts, whereas it remained lower in heterozygous (7.3±
1.1%) and wild-type mice (3.1±0.4%). Starting from the 10th week of
treatment the percentage of monocytes in HO-1-deﬁcient mice
returned to the initial value. Then it gradually rose until week 18,
but again decreased at the end of the experiment (Fig. 4A). Therewere
no differences in the frequency of leukocyte subpopulations between
animals that survived until the 28th week or died in the course of the
experiment.
Fig. 4. Percentages of (A) monocyte, (B) lymphocyte, and (C) granulocyte sub-
populations in the blood of mice of various HO-1 genotypes treated with DMBA/PMA.
FACS analysis of SSC/FSC dot-blots (*Pb0.05 HO-1−/− vs HO-1+/+, $Pb0.05 HO-1+/− vs
HO-1+/+). Each point represents the mean±SE.
Fig. 5. Concentrations of (A) KC, (B) VEGF, (C) VEGF-R1, (D) TNFα, and (E) IL-12 in
tumor lysates measured using colorimetric ELISA at the end of the experiment (*Pb0.05
vs HO-1+/+). Each bar represents the mean+SE.
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and proangiogenic cytokines in tumors. Thus, the nodules growing in
wild-type animals tended to produce less KC, VEGF, and VEGF-R1
(Figs. 5A, B, and C) than HO-1+/− or HO-1−/− tumors. In contrast,
they contained higher levels of TNFα and IL-12, proteins displaying
some antitumoral activities (Figs. 5D and E). Production of IL-6, SDF-
1α, and G-CSF was similar in tumors of the various HO-1 genotypes
(data not shown).
Despite the distinct production of proinﬂammatory cytokines,
pathomorphological investigation did not show any apparent differ-
ences in the inﬂammatory inﬁltrates. The semiquantitative assess-
ment showed that the average grade of inﬂammatory inﬁltration was
1.250±0.229, 1.0±0.365, and 1.670±0.333 in HO-1+/+, HO-1+/−,
and HO-1−/− individuals, respectively. The inﬁltrates contained
mononuclear cells, neutrophils, eosinophils, and mast cells and were
similar in tumors of all genotypes.
Labeling of endothelial cells using isolectin binding has demon-
strated that all lesions were well vascularized (Supplementary Fig.
S1A). The results did not show, however, any genome-speciﬁc
differences. Also in pathomorphological assessments no clear differ-
ences in vascularization were noticed (data not shown). Nevertheless,
semiquantitative evaluation of erythrocyte extravasation suggested
an HO-1-dependent trend, in which HO-1-deﬁcient mice had the
lower rate of intratumoral bleeding (the average extravasation grade
was 0.615±0.320, 0.250±0.207, and 0.200±0.211 for HO-1+/+, HO-
1+/−, and HO-1−/− animals, respectively).
Unexpectedly, although HO-1-deﬁcient tumors grew faster, we
were unable to ﬁnd any differences in the number of proliferating,PCNA-positive cells in HO-1+/+, HO-1+/−, and HO-1−/− mice
(Supplementary Fig. S1). Also analysis of mitogenic ﬁgures in
histological specimens did not indicate the genotype-related trends
(data not shown).
Additionally we performed semiquantitative histological analysis
of necrotic areas. Here we found a trend toward the higher necrosis
rate in HO-1-deﬁcient animals: the average necrosis grade was 0±0,
0.167±0.192, and 0.400±0.281 for HO-1+/+, HO-1+/−, and HO-
1−/− mice, respectively. It is difﬁcult to judge, however, if the more
pronounced necrosis in HO-1−/− tumors was a direct consequence of
HO-1 deﬁciency and increased cell mortality or an indirect effect of
larger volumes of tumors.
Effect of DMBA/PMA treatment on expression of cytoprotective genes
Because local application of DMBA/PMA can potentially induce a
systemic oxidative stress, and HO-1-deﬁcient mice are more prone
to systemic oxidative challenge, we checked the expression of
antioxidative genes in the livers. Using qRT-PCR we compared the
expression patterns in healthy animals and in mice after the 28-
week exposure to carcinogens. First, we found that the level of HO-1
in healthy individuals was very low and similar in HO-1+/+ and HO-
1+/−mice. In response to carcinogens it increased potently, with the
strongest reaction in wild-type and much weaker in heterozygous
animals (Fig. 6A). Carcinogens led also to signiﬁcant upregulation of
SOD-1, SOD-2, GSTA-1, Thrx-2, and BVR, to similar extents in mice of
all HO-1 genotypes (Figs. 6B–F). On the other hand, expression of GR
and catalase was higher in the healthy HO-1+/− group than in HO-
1+/+ and HO-1−/− (Figs. 6G and H). In response to carcinogens it
was signiﬁcantly augmented in the wild-type and knockout mice,
but remained relatively stable in heterozygotes. Ferritin was
similarly expressed before and after treatment in all experimental
groups (Fig. 6I). These changes may indicate a systemic oxidative
stress induced by carcinogens, which is not meaningfully inﬂuenced
by the level of HO-1 expression. It is also suggested that the differences
observed in thedevelopmentof tumorsdonot result fromdifferent levels
of systemic oxidative response in HO-1+/+, HO-1+/−, and HO-1−/−
animals.
Fig. 6. Expressionof cytoprotective genes in the livers of healthy andDMBA/PMA-treatedmiceof various genotypesmeasuredusing qRT-PCR. (A)HO-1, (B) SOD-1, (C) SOD-2, (D)GSTA-1,
(E) Thrx-2, (F) BVR, (G)GR, (H) catalase, (I) ferritin. EF2wasusedas a constitutive housekeeping gene (*Pb0.05vsHO-1+/+, #Pb0.05vshealthymice). Each bar represents themean+SE.
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Neither incubationwith DMBA for 24–72 h nor treatmentwith c-Myc
inﬂuenced signiﬁcantly viability or proliferation of primary skin ﬁbro-
blasts of thevariousgenotypes, as estimatedby3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide reduction, lactate dehydrogenase
activity, andBrdU incorporation assays (data not shown). Interestingly, in
vitro experiments showed that HO-1 deﬁciency may increase the FBS-
inducedproliferationofﬁbroblasts (SupplementaryFig. S2A) andreduced
their motility (Supplementary Fig. S2B). Interestingly, HO-1 expression
strongly inﬂuenced the ability of c-myc-transformed ﬁbroblasts to grow
in semiliquid agarose in clonogenic assays. Wild-type cells were able to
form many more colonies than HO-1+/− or HO-1−/− cells (Supplemen-
tary Fig. S2C). Treatment with DMBA, regardless of concentration and
time of exposure, did not transform the ﬁbroblasts in vitro (data not
shown).
Then, we used the GEArray Q series assay (SuperArray Biosciences)
to screen the expression proﬁle of 23 genes regulating cell cycle in the
primaryﬁbroblasts. This allowedus to select thep21and cyclin-Dgenes,
which were differentially expressed in HO-1+/+, HO-1+/−, and HO-
1−/− cells. Quantitative RT-PCR analysis conﬁrmed that lack of HO-1 in
resting cells was associated with increased expression of p21 and
reduced expression of cyclin-D1 and cyclin-D2. The level of cyclin-D3
turned out to be independent of HO-1 status (Supplementary Figs. S3A–
D). DMBA (5 μM, 72 h) only weakly upregulated p21 expression in the
wild-type cells, but strongly increased it in the HO-1+/− and HO-1−/−
ﬁbroblasts. Transformation with c-myc did not inﬂuence p21 in any
group (Supplementary Fig. S3A).
Cyclin-D1was upregulated by DMBA in a similarway—the effect was
much stronger in the HO-1+/− andHO-1−/− than in thewild-type cells.
Interestingly, expression of cyclin-D1 after c-myc transformation was
higher in HO-1+/+ than in HO-1+/− and HO-1−/− ﬁbroblasts (Supple-
mentary Fig. S3B). A similar tendency was found for cyclin-D2—the
upregulation in response to DMBA was apparent only in HO-1−/−
ﬁbroblasts, whereas in cells transduced with c-myc, like in the control
cells, cyclin-D2 remained at a much lower level (Supplementary Fig.
S3C). Expression of cyclin-D3 was not signiﬁcantly inﬂuenced by DMBA
or c-Myc, regardless of the HO-1 status (Supplementary Fig. S3D). We
also demonstrated that exposure of thewild-typeﬁbroblasts toDMBAor
their transduction with c-myc strongly activates Akt and S6 kinases. Incontrast, either HO-1+/− or HO-1−/− cells displayed much higher
activation of both kinases under control conditions, which was not
further augmented in response to the treatments (Supplementary Figs.
S3E, F, and G).
Discussion
The major ﬁndings of our study are: (i) HO-1-deﬁcient mice are
more vulnerable to DMBA/PMA-induced skin injury, (ii) lack of
HO-1 results in the development of large, but benign, papillomas
in response to DMBA/PMA treatment, whereas HO-1 expression
seems to facilitate a transformation of growing tumors to
malignant carcinoma; and (iii) HO-1-deﬁcient ﬁbroblasts exposed
to DMBA demonstrate more pronounced upregulation of p21,
cyclin-D1, and cyclin-D2 expression, but are less susceptible to c-
myc-mediated transformation. Thus, HO-1 can protect healthy
skin from the initial injury caused by carcinogens, but in growing
tumors it can promote malignancy.
An association between induction of HO-1 and tumor growth or
malignancy was indicated already in 1997 by Goodman and colleagues
[7], who demonstrated a severalfold elevation of HO-1 expression in
rapidly growing renal carcinomacells. This increase could be induced by
a factor(s) released by the tumors or could be a general response to
oxidative stress or hypoxia. Generally, it appeared to promote tumor
progression [7].
We demonstrated that mice with a low or no HO-1 expression (HO-
1+/− and HO-1−/−) developed the ﬁrst DMBA/PMA-induced lesions
earlier then their wild-type counterparts. Indications of a similar,
potentially protective role in chemically induced carcinogenesis were
reported for other antioxidative genes,NADPH:quinoneoxidoreductase-
1 (NQO-1) and NF-E2-related factor (Nrf2) [30,31]. Namely, treatment
with DMBA alone led to the development of skin tumors in about 50% of
the NQO-1−/−mice but in none of the wild-type individuals [30]. Also,
when the DMBA/PMA two-step model of carcinogenesis was used, the
NQO-1−/− mice developed larger tumors at a greater frequency than
their wild-type littermates [31]. Likewise, intragastric administration of
benzo[a]pyrene to Nrf2-deﬁcient mice resulted in a signiﬁcantly higher
burden of gastric neoplasia than in wild-type animals [31].
Our results also support the clinical analyses, in which carriers of
more active variants of the HO-1 promoter were more frequent among
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carcinoma in betel chewers, lung adenocarcinoma in heavy smokers,
and breast carcinoma in women subjected to iron supplementation
[27,28,32–35]. This suggests a protective role for HO-1 at least against
carcinogens associated with induction of oxidative stress.
Although mean latency to the ﬁrst lesion is very similar in HO-
1−/− and HO-1+/− animals, the resulting tumors are different: HO-
1−/−mice develop a few, but large, lesions, and HO-1+/−mice much
smaller but very numerous ones. The mechanism underlying these
differences is not clear. One can hypothesize that lack of HO-1 may
lead to a higher apoptotic rate of affected cells in skin treated with
carcinogens and thereby to a reduced rate of initiation, whereas after
transformation it may facilitate cell proliferation. This supposition
might be supported by the observation of increased proliferation of
ﬁbroblasts isolated from HO-1−/−mice, although it should be kept in
mind that the inﬂuence of HO-1 on the cell cycle is tissue-speciﬁc [32].
Additionally, we noticed the augmented activity of Akt kinase and its
effector S6 ribosomal protein in resting HO-1+/− and HO-1−/− cells.
This pathway regulates proliferation, apoptosis, and growth in a
variety of cell types [36]. Its inhibition contributes to the antineo-
plastic effects of several drugs, such as dibenzoylmethane [37],
enzastaurin [38], resveratrol [39], xanthorrhizol [40], or bromelain
[41]. Expression of constitutively active Akt increases the susceptibil-
ity of mice to the induction of mammary tumors of epithelial origin by
DMBA [36]. Thus it seems possible that the increased activity of Akt in
HO-1-deﬁcient cells might facilitate the growth of tumors.
HO-1 knockout mice displayed the highest mortality and the
smallest body weight gain in the time course of the experiments.
However, large tumors developed by HO-1−/− individuals remained
benign papillomas, in contrast to the dysplastic lesions found in HO-
1+/− and HO-1+/+ mice. It must be stressed that the low number of
HO-1−/− animals with malignant carcinoma at the end of the
experiment did not result from an earlier death of individuals with
advanced tumors in this group. Apart from tumors harvested from the
surviving animals at the end of the study (at week 28), we also
collected tumors from animals that died earlier, starting from week
13. The results (not shown) were the same as for tumors taken on
week 28: all HO-1−/− animals dying between weeks 13 and 28
developed benign lesions, whereas the ﬁrst carcinoma in a wild-type
individual was found already at week 16. Therefore, the differences
between the proportions of malignant tumors in mice of different
genotypes were not caused by preterm deaths of HO-1−/− animals
with more advanced tumors and survival of those with milder lesions.
A discrepancy between the growth and the malignancy of tumors
was also observed in p53-deﬁcient mice. In this model, opposite to
HO-1 deﬁciency, the p53 knockout mice developed smaller DMBA-
induced papillomas than their wild-type counterparts. However, the
malignant conversion of these small papillomas to squamous cell
carcinomas was markedly accelerated [42].
We suppose that increasedmortality of HO-1 knockouts observed in
the last part of the experiment might not be directly associated with
tumormalignancy, but rathermight be caused by a higher sensitivity to
inﬂammatory response to PMA treatment, especially in older animals.
Indeed, Poss and Tonegawa have shown that HO-1-deﬁcient mice
develop chronic inﬂammation and augmented sensitivity to oxidative
injury, the effect increasing with age [43]. Here we demonstrated that
HO-1 deﬁciency was also associated with a higher proportion of
monocytes in the blood of untreated animals and with a much stronger
increase in monocyte fraction in response to the ﬁrst PMA treatment,
which may indicate a stronger inﬂammatory response.
We also found that the local concentrations of VEGF were higher in
HO-1-deﬁcient than in wild-type individuals. This was surprising,
because VEGF is positively regulated by HO-1 in many cell types
cultured in vitro [3], and its upregulation canmediate the proangiogenic
activities of HO-1 in some cancers [11,20,24,26]. Possibly, the higher
tumoral concentration of VEGF in the HO-1-deﬁcient mice is rather anindirect effect, resulting, for example, from upregulation of some
proinﬂammatory mediators. In contrast to the healthy tissues, in the
inﬂamed organs HO-1 is known to inhibit VEGF production [44]. One
such mediator might be KC, the murine ortholog of human IL-8, which
directly upregulates VEGF expression in an NF-κB-dependent manner
[45]. The KC concentration was much higher in HO-1−/− and HO-1+/−
than in HO-1+/+mice (Fig. 5A). Alternatively, larger tumors growing in
HO-1-deﬁcient mice could be more hypoxic and therefore might
produce more VEGF. This supposition might be supported by a very
similar increase in expression of VEGF-R1 (Fig. 5C), which is directly
upregulated by hypoxia [46,47].
It seems that production of proinﬂammatory cytokines is not a
signiﬁcant factor inﬂuencing themalignant conversion of papilloma in
our model. In HO-1+/− and HO-1−/− tumors, the local concentrations
of all cytokines studied were similar, whereas the frequency of
dysplastic foci wasmuch higher in heterozygotes. It has been reported
that conversion of papilloma to SCC can be accelerated by oxidative
stress, as antioxidants inhibit PMA-dependent promotion of carcino-
genesis [48–49].We observed an upregulation of several antioxidative
enzymes in the livers of animals treated with DMBA/PMA, which
indicates the induction of systemic oxidative stress. However this
response was similar in all experimental groups, regardless of the HO-
1 genotype. Thus, it seems that the antioxidative potential of HO-1
does not play a major role in our system. Furthermore, a lack of HO-1
did not facilitate but actually attenuated the malignant conversion.
Treatment with DMBA is known to induce p21 and cyclin-D1 in
carcinoma [50]. Experiments performed on primary ﬁbroblasts isolated
from the skin of mice of the various HO-1 genotypes conﬁrmed the
induction of p21 and cyclin-D1 and demonstrated that this response
was much stronger in HO-1+/− and especially in HO-1−/− cells than in
their wild-type counterparts. Thus, it seems that HO-1 may to some
extent attenuate the effects of DMBA, which we also observed in the
growing tumors in vivo. Interestingly, it was reported that p21
deﬁciency in DMBA-treated mice resulted in the development of more
undifferentiated tumors,with a high frequency of anaplastic spindle cell
carcinomas, indicating the protective role of p21 against progressive
malignancy [51]. We found the lowest rate of dysplastic conversion in
HO-1 knockouts, in which the ﬁbroblastic expression of p21 was the
highest, whichmight suggest the involvement of this pathway in HO-1-
dependent differences in DMBA/PMA carcinogenesis. However, in
contrast to in vitro cell cultures, we did not ﬁnd statistically signiﬁcant
differences in p21 expression in heterogeneous tumor tissue (data not
shown).
We also compared the inﬂuence of HO-1 on the transformation of
primary ﬁbroblasts overexpressing c-myc after retroviral transduction.
This proto-oncogene is a keyplayer in the cell cycle, actingamongothers
through inhibition of p21 and upregulation of cyclins-D [52–54]. In
contrast tomodulation of DMBA activity, lack of HO-1 reduced the effect
of c-myc overexpression on the cell-cycle-regulating genes. Thus, the
levels of cyclin-D1 and -D2were signiﬁcantly lower in both resting and
c-myc-overexpressing ﬁbroblasts. Accordingly, the c-Myc-induced
transformation and clonal growth in the semiliquid agarose were
completely ineffective in theHO-1-deﬁcient cells,which can support the
observation of reducedmalignant transformation in the HO-1 knockout
mice. Furthermore, the lack of HO-1 reduced migration capabilities of
ﬁbroblasts. A signiﬁcantpositive role forHO-1 in cellmotilitywas earlier
observed in endothelial progenitor cells [55] and keratinocytes [56].
Thus, one can suppose that reduced motility of cells with a low HO-1
expression may be associated with the lower inﬁltration of tissues and
less malignant phenotype of cells.
In summary, DMBA/PMA treatment of HO-1 knockout mice induced
the formationof skin lesions at the earliest, and resulting tumors grew the
biggest, which was accompanied by increased mortality of the animals.
However, histological analysis showed that the tumors remained benign
papillomas. In contrast, tumors in the wild-type mice were smaller and
developed later, but much more effectively underwent malignant
1725H. Was et al. / Free Radical Biology & Medicine 51 (2011) 1717–1726conversion. Heterozygous animals grew relatively small, but very
numerous, dysplastic tumors. Thus, HO-1 is protective against cancer
initiation, but then seems to facilitate clonal promotion. These data also
suggest that patients with a low expression of HO-1 may be more
susceptible to development of SSC after exposure to carcinogens.
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